University of the Pacific Thomas J. Long School of Pharmacy
The skill set and clinical experience gained from our PharmD program open new doors to the many settings where pharmacists play a key role -- from hospitals to pharmaceutical research and development. Through each component of our PharmD curriculum, students learn how to become a pharmacist who leads with excellence.
From the first semester, students develop patient-care skills that are integrated throughout the PharmD curriculum, exposing them to the administrative, pharmaceutical, social, behavioral and clinical science aspects of the field of pharmacy. This combination allows students to develop a solid foundation of practical training by gaining patient care experience across a wide variety of settings.
The School is home to a robust interprofessional education (IPE) curriculum that supports PharmD students. Through IPE, students engage in case-based learning, simulations, peer teaching, telehealth simulations and innovative gaming techniques such as escape room scenarios. They also apply teamwork skills and learned concepts in interprofessional practice experiences during their Introductory Pharmacy Practice Experiences (IPPE) and Advanced Pharmacy Practice Experiences (APPE).
The Thomas J. Long School of Pharmacy is committed to the success of our students. To ensure that each of our PharmD graduates are prepared for their careers, we offer a first-of-its- kind, immersive three-week residential California Practice Standards and Jurisprudence Examination (CPJE) and North American Pharmacist Licensure Exam (NAPLEX) preparatory program.
This comprehensive program is designed to build on students' strengths through targeted practice sessions and engaging reviews and complements other available resources. In their third year, all students also complete 'Rx Prep' to begin early preparation for licensure exams.
At Pacific, students have the opportunity to work alongside faculty members on cutting-edge research. Current projects focus on novel drug delivery systems, innovative drug design and forward- thinking approaches to patient care. Our faculty have also earned international recognition for their research on diabetes and consumer products.
While pursuing their PharmD, students can customize their education through two distinct and dynamic pathways: clinical pharmacology and entrepreneurship.
The clinical pharmacology pathway prepares students with a comprehensive understanding of clinical drug development and equips them to contribute to evidence-based decision-making in drug therapy and development.
The entrepreneurship pathway provides future scientists with a strong foundation in pharmaceutical business operations and the entrepreneurial skills needed to launch and lead ventures focused on novel drug products and medical devices.
The School's dual-degree programs combine the clinical training of the PharmD with immersive research through the Pharmaceutical and Chemical Sciences Program, preparing PharmD/MS and PharmD/PhD graduates for high- demand roles in industry and academia.
Learn more and apply today at Pacific.edu/PharmD
University of the Pacific
Thomas J. Long School of Pharmacy
Berit Gundersen, PharmD
1851
1955
530
Doctor of Pharmacy (PharmD)
Pathways:Clinical pharmacologyEntrepreneurship
Dual-degrees:PharmD/MSPharmD/PhD
3 years
In 2024, following a rigorous review, the Accreditation Council for Pharmacy Education (ACPE) granted Pacific's doctor of pharmacy program an eight-year reaccreditation.
2025-26: $235,784
Final application deadline: June 6, 2025
Tony Williams, Director of RecruitmentOffice of Pharmacy Admission209.932.3600pharmdadmission@pacific.edu Pacific.edu/PharmD
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
Strategic Collaborations and Local Innovations Reshape the $24.58 Billion Market
The Asia Pacific diabetes market is set for growth, expected to expand annually by 8.8% to reach $24.58 billion by 2025. Significant trends include increased diabetes prevalence and digital health adoption, driving demand for monitoring and therapeutic solutions. Enhanced policy reforms and insurance coverage are fostering market access, while rising competition is reshaping the landscape with strategic alliances and localized innovation. The comprehensive report analyzes diagnosis and monitoring devices and therapeutics, exploring market dynamics and opportunities. Get insights on the competitive environment, segment growth, and investment potential within the diabetes market in Asia Pacific. Asia-Pacific Diabetes Devices and Therapeutics Market Dublin, July 08, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Diabetes Devices and Therapeutics Market Investment Opportunities - Q2 2025 Update" report has been added to diabetes market in Asia Pacific is expected to grow by 8.8% on annual basis to reach US$24.58 billion in 2025. The diabetes market in the region has experienced robust growth during 2020-2024, achieving a CAGR of 9.4%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 7.4% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 22.59 billion to approximately USD 35.43 billion. This report provides a detailed data-centric analysis of the diabetes industry in Asia Pacific, covering market opportunities and analysis across a range of diagnosis and monitoring devices, therapeutics, domains. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of diabetes market dynamics, market size and forecast, and market share statistics. The market features participation from both established multinational corporations and emerging regional manufacturers. The competitive environment is characterized by varied regulatory frameworks and economic conditions across the Asia Pacific. Publications from the past 12 months indicate a segmented market with regional differentiation in product offerings and market strategies. The market is evolving with a mix of longstanding multinational entities and agile local innovators. With an expected trend toward consolidation and strategic collaborations, the next 2-4 years will likely see a reshaping of competitive dynamics focused on localized product innovation and regulatory alignment. The diabetes devices and therapeutics market in Asia Pacific is being reshaped by increased diabetes prevalence, the adoption of digital health solutions, and evolving policy frameworks. These drivers are expected to intensify over the next 2-4 years, leading to more targeted and data-supported approaches in managing diabetes across diverse regional Rising Diabetes Prevalence and Healthcare Demand Recent publications (2023-2024) report a measurable increase in diabetes cases across Asia Pacific, with significant examples in China, India, and several Southeast Asian nations. Rising incidences of type 2 diabetes are increasing the need for effective monitoring and therapeutic interventions. Demographic shifts (aging populations, urbanization) and evolving lifestyle patterns drive the demand. Adjustments in healthcare financing and insurance reforms across the region support wider access to diagnostic devices and therapies. Anticipate a steady intensification in demand for devices that integrate daily management tools. Healthcare systems will likely expand investments in diabetes-related technologies to address the growing burden. Leverage Digital Integration and Remote Monitoring Solutions Recent regional studies highlight the increased adoption of continuous glucose monitoring (CGM) systems and telehealth services, especially in Japan and South Korea. Various Asia Pacific markets have initiated pilot programs integrating remote monitoring with traditional care models. Technological progress and supportive regulatory policies in digital health are key drivers. Increased investments in digital infrastructure by governments and insurers foster the adoption of connected devices. Expect further penetration of digital health solutions, with remote monitoring playing a more central role in clinical decision-making. Enhanced data analytics are likely to support more personalized diabetes management strategies regionally. Activate Policy Reforms and Insurance Coverage Enhancements Recent reforms in countries like Singapore and Australia have expanded reimbursement for diabetes management devices. Publications from late 2023 detail shifts in regulatory frameworks that now favor broader insurance coverage for innovative therapeutics. Government initiatives focused on reducing long-term healthcare expenditures and improving chronic disease management drive policy changes. Broader insurance reforms align with healthcare objectives to support preventive care and early intervention. The convergence of supportive policies and insurance incentives will further facilitate market access for new devices and therapies. Ongoing regulatory clarifications will likely encourage domestic and international investments in the region. Map Key Players and New Entrants Major global companies continue investing in research and development to maintain their regional presence. Local manufacturers, particularly in India and China, are entering the market with products tailored to regional cost structures and clinical needs. New entrants are leveraging localized expertise to address gaps in the current market, supported by regional demand for cost-effective solutions. Evaluate Strategic Collaborations and Market Consolidation Recent transactions in the last 12 months have seen collaborations between device manufacturers and healthcare providers in Southeast Asia and Australia. Strategic alliances emerge as companies seek to expand their product portfolios and market reach through mergers and acquisitions. The competitive landscape will likely experience increased consolidation as larger players acquire or partner with regional innovators. Firms that successfully navigate regulatory requirements and invest in localized development are positioned to gain competitive advantages. Forecast Competitive Shifts Continued regulatory reforms and heightened demand for diabetes management solutions will attract further competition. Specialized product developments addressing country-specific needs may lead to a more segmented competitive environment. Investment in research, strategic partnerships, and adaptation to local regulatory environments will be critical for sustaining market leadership. A bundled offering, combining the following 12 reports, covering 480 tables and 648 figures: Asia Pacific Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Australia Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) China Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) India Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Indonesia Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Japan Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Malaysia Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Philippines Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Singapore Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) South Korea Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Taiwan Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Thailand Diabetes Devices and Therapeutics Market Opportunity and Future Growth Dynamics (Databook) Scope for Each Report Diabetes Devices and Therapeutics Market Share by Category Diagnosis and Monitoring Devices Therapeutics Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices Blood Glucose Monitoring Devices Insulin Delivery Devices Diabetes Management and Mobile Applications Artificial Pancreas Devices Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices Self-Monitoring Blood Glucose Devices Continuous Blood Glucose Monitoring Devices Test Strips Lancets Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices Insulin Pumps Insulin Pens Insulin Syringes Diabetes Devices and Therapeutics Market Share by Therapeutics Oral Anti-Diabetic Drugs Insulin Non-Insulin Injectable Drugs Combination Drugs Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs Alpha-Glucosidase Inhibitors DPP-4 Inhibitors SGLT-2 Inhibitors Diabetes Devices and Therapeutics Market Share by Insulin Basal or Long-Acting Bolus or Fast-Acting Traditional Human Insulin Drugs Insulin Biosimilars Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs GLP-1 Receptor Agonists Amylin Analogue Diabetes Devices and Therapeutics Market Share by Combination Drugs Combination Insulin Oral Combination Diabetes Devices and Therapeutics Market Share by Route of Administration Subcutaneous Intravenous Others Diabetes Devices and Therapeutics Market Share by Type of Diabetes Type 1 Diabetes Type 2 Diabetes Diabetes Devices and Therapeutics Market Share by Distribution Channels Online Pharmacies Hospital Pharmacies Retail Pharmacies Diabetes Devices and Therapeutics Market Share by End User Hospitals Diabetes Clinics Homecare Reasons to buy Comprehensive understanding of market structure and dynamics: Gain a detailed view of the diabetes devices and therapeutics market, including category-level segmentation (Diagnosis & Monitoring Devices and Therapeutics) and sub-segmentation by product type, route of administration, type of diabetes, distribution channel, and end user. Identify high-growth segments and strategic investment areas: Use segment-wise market sizing and forecasting to identify opportunities in areas such as continuous glucose monitoring, insulin delivery technologies, oral anti-diabetic drugs, and biosimilars. Tailor your market entry or expansion strategies accordingly. Benchmark performance across distribution and care settings: Access share analysis across online, hospital, and retail pharmacies, and evaluate usage patterns across hospitals, diabetes clinics, and homecare to support channel-specific planning and resource allocation. Key Attributes: Report Attribute Details No. of Pages 840 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $26.63 Billion Forecasted Market Value (USD) by 2029 $35.43 Billion Compound Annual Growth Rate 7.4% Regions Covered Asia Pacific For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Asia-Pacific Diabetes Devices and Therapeutics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Yahoo
Sino Biopharma spends $951m to acquire China-based LaNova Medicines
Hong Kong-listed Sino Biopharmaceutical will acquire China-based oncology specialist LaNova Medicines in a deal that will not exceed $951m, representing one of the largest transactions within the Asia-Pacific pharmaceutical arena this year. Sino already owns a 4.91% stake courtesy of an investment in November 2024, with the company now seeking to purchase the remaining 95.09% it does not own. At the time, Sino spent 142 million yuan ($19.80m) to initiate its ownership involvement with the biotech. The net payment made by Sino to acquire LaNova will be approximately $500.9m, a figure that excludes the estimated cash and bank deposits, according to a company document outlining the terms of the transaction. Following the completion of the nearly billion-dollar deal, LaNova Medicines will become an indirect wholly owned subsidiary of Sino. A timeline of 30 business days has been set by the companies to finalise the deal. Sino revealed the acquisition agreement after trading hours on 15 July. The share price in the company had climbed 3.6% by market close. LaNova's drug development focuses on tumour immunity and the tumour microenvironment. The company has particular emphasis on antibody-drug conjugates (ADCs) and has built several platforms within this modality. Sino stated the acquisition would strengthen its research and development capabilities, subsequently enhancing competitiveness and innovation in the oncology market. LaNova's pipeline has already been raided twice by US big pharma companies. In 2023, AstraZeneca licensed LM-305, a G-protein targeting-ADC, for $600m. A year later, MSD outlaid more than $3bn to secure global rights to LM-299, an anti-PD-1/VEGF bispecific antibody. According to Sino, LaNova Medicines has two projects in the registration clinical stage, six projects in the Phase I/II clinical trial stage, and more than ten projects in the preclinical research stage. In a statement, Sino said: 'Through the in-depth synergy and integration of the advantageous resources of both parties, not only will the potential value of LaNova Medicines be fully released, but also [Sino's] innovation capability will be comprehensively enhanced." The company added that the transaction will help towards its 'strategic goal of advancing towards a world-class innovative pharmaceutical enterprise'. China's economy grew 5.2% year-on-year in Q2, defying the lingering effects of US President Trump's trade war and reinforcing its position as the world's top exporter. This economic resilience is mirrored in China's growing role in the global oncology market. Despite economic pressures, licensing promising drug candidates from Chinese biotechs is becoming a well-trodden path for many US big pharma companies. Licensing deals between US and Chinese biopharma companies hit record highs last year, a 280% increase from 2020, according to analysis by GlobalData. Across big pharma, transactions rose 66% from $16.6bn in 2023 to $41.5bn in 2024, demonstrating that China is still the go-to place to discover pipeline candidates. For deals specific to US companies, the analysis found that total deal value rose from $15.7bn in 2023 to $21.3bn in 2024. GlobalData is the parent company of Pharmaceutical Technology. "Sino Biopharma spends $951m to acquire China-based LaNova Medicines" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
USA Today
04-07-2025
- USA Today
Nevada Rep. Mark Amodei explains yes vote on Trump's budget bill, Medicaid changes
Only one member of Congress from Nevada voted in favor of President Donald Trump's budget bill and its Medicaid cuts: Rep. Mark Amodei. Trump plans to sign the bill into law at 2 p.m. Pacific time July 4. After the U.S. House approved the bill July 3, Amodei released a lengthy statement explaining his decision to support what he called historic legislation to address the Biden administration's mismanagement. 'As with any major reform bill, the One Big Beautiful Bill is a balancing act,' he said, referring to its legislative name inspired by Trump's language. 'I have long believed that we can't let perfect be the enemy of good, and our work won't stop here in getting Nevadans the relief they need.' Amodei disputed claims the bill is only a handout to the wealthy and characterized it as helping everyday working families. Amodei's bill highlights Among Amodei's highlights for the bill are that: 'Claims that this bill harms veterans are nothing more than political scare tactics and gaslighting,' he said. 'The legislative text contains no provisions explicitly targeting veterans, and veterans receiving VA benefits will continue to do so without interruption.' Amodei on Medicaid changes Amodei, a Republican who represents the top half of Nevada, noted that discussions around the bill have focused on Medicaid. Sen. Catherine Cortez Masto, a Nevada Democrat, hammered the bill the day before its passage, calling it 'mean and cruel.' She noted that estimates show 114,500 Nevadans are expected to lose health care coverage. Northern Nevada HOPES, which serves low-income patients, said the bill will force a 30% reduction in the number of people it can said Medicaid has exploded in size since it started in 1965. 'Since the enactment of the Affordable Care Act,' his news release said, 'Medicaid has shifted away from its original mission of serving the traditional low-income population, evolving instead into a de facto state-run universal healthcare system.' In fiscal year 2023, he said, Nevada spent 30% of its budget on Medicaid, $5.6 billion. 'The One Big Beautiful Bill addresses and reins in these excessive Medicaid costs by establishing commonsense work requirements for able-bodied adults without young dependents,' Amodei said. 'In addition, the bill strengthens program integrity measures that protect Medicaid resources for the most vulnerable such as children, pregnant women, people with disabilities and low-income families.' More: 'Cruel' Medicaid cuts in Trump budget bill cuts to hurt Nevada, Sen. Cortez Masto says Funding for rural hospitals There's a balancing act, he said, between reining in out-of-control Medicaid spending and protecting Nevada's hospitals and health clinics. To offset decreases in Medicaid funding for hospitals, Republicans added the Rural Hospital Stabilization Fund to the bill. This, Amodei said, 'will provide $50 billion in relief from 2028 through 2032 for rural hospitals.' Pat Kelly of the Nevada Hospital Association said it's unclear how much help it'll bring. At Cortez Masto's news conference, Kelly said that the federal budget bill's changes to the provider tax rate will decrease hospital funds. 'The total effect by state fiscal year 2029 on Nevada hospitals,' he said, 'will be a loss of $618 million in payments.' Kelly noted the $50 billion fund mentioned by Amodei in the federal budget bill. 'But that provision,' he said, 'is not just for rural hospitals. It's for all providers in rural areas so we're not sure how much is going to be available for hospitals. If there's a group that truly needs our support, it's our rural hospitals.' Amodei said the bill gives the state two years to prepare for changes to the Medicaid provider tax supporting hospitals. 'A perfect solution to healthcare costs has eluded us again,' he said, 'but it will be interesting to see what the Centers for Medicare and Medicaid Services do with implementation of these new Medicaid policies and future rules and regulations. 'I look forward to continuing to work with CMS, the Nevada Health Authority, and our local stakeholders on these issues.' Mark Robison is the state politics reporter for the Reno Gazette Journal, with occasional forays into other topics. Email comments to mrobison@ or comment on Mark's Greater Reno Facebook page.
